Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Transcode Therapeutics, Inc.RNAZ · Entity 8499 | Director | June 14, 2024 | June 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Transcode Therapeutics, Inc.
Report date June 14, 2024 · Filed June 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2034-06-13 | Direct | 70,000 |
Reported balance
After 2024-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-14 · Grant · Acquired 70,000 · Balance 70,000 F1: Fifty percent (50%) of the shares subject to this option vested and became exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Fifty percent (50%) of the shares subject to this option vested and became exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2024 Filed Jun 18, 2024 20:16 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001104659-24-072825 · tm2417512-3_4seq1.xml · derivative · entry 1 Manting Erik · CIK 0001856180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: Fifty percent (50%) of the shares subject to this option vested and became exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 19, 2023 Filed May 20, 2023 00:09 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001104659-23-062816 · tm2316383-6_4seq1.xml · derivative · entry 1 Manting Erik · CIK 0001856180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2033-05-18 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full on December 31, 2023, subject to the Reporting Person's continued service at such time. Read SEC document |
| May 10, 2023 Filed May 10, 2023 22:13 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | GrantStock Option (Right to Buy) · Derivative | 9,500 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001104659-23-058582 · tm2315294-3_4seq1.xml · derivative · entry 1 Manting Erik · CIK 0001856180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2033-05-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 10, 2024 and (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 00:24 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | GrantStock Option (Right to Buy) · Derivative | 9,500 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001104659-22-073634 · tm2219203-1_4seq1.xml · derivative · entry 1 Manting Erik · CIK 0001856180 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2032-06-21 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.